PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b

NCT01066819 | Completed Results

• 1 other identifier: MV21542
• Study Type: observational
• Target: 1,656
• Locations: 2 countries
• Sites: 106

Brief Summary

This observational study will assess predictors of early on-treatment and sustained virological response in treatment-naïve patients with chronic hepatitis C initiated on treatment with Pegasys (peginterferon alfa-2a) or peginterferon alfa-2b and ribavirin. Data will be collected during the treatment period (24 or 48 weeks) and 12 and 24 weeks after the end of treatment. Target sample size is \<2000.

Conditions

Hepatitis C, Chronic

Outcome Measures

Primary Outcomes (6)

• Percentage of Participants With Sustained Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population

  Sustained virological response (SVR) was defined as virological response (VR) at 24 weeks after end of treatment (EOT). Virological response was defined as hepatitis C virus ribonucleic acid (HCV RNA) of \<15 international units per milliliter (IU/mL) as assessed by COBAS AmpliPrep/COBAS TaqMan (CAP/CTM) or another HCV RNA test with at least the same degree of sensitivity. The CAP/CTM test is an in vitro nucleic acid amplification test for the quantification of HCV. This test possesses a high sensitivity (lower limit of detection \[LLOD\] 15 IU/mL) and a broad linear range of quantification (43 IU/mL up to 69 million IU/mL) in all HCV genotypes. The SVR is reported in treatment naive HCV mono-infected modified all-treated (mTRT) population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.

  At 24 weeks (Wk) after EOT

• Percentage of Participants With Sustained Virological Response by Type of Peginterferon and Genotype in Per Protocol Population

  Sustained virological response was defined as VR at 24 weeks after EOT. Virological response was defined as HCV RNA of \<15 IU/mL as assessed by CAP/CTM or another HCV RNA test with at least the same degree of sensitivity. The CAP/CTM test is an in vitro nucleic acid amplification test for the quantification of HCV. This test possesses a high sensitivity (LLOD 15 IU/mL) and a broad linear range of quantification (43 IU/mL up to 69 million IU/mL) in all HCV genotypes. The SVR is reported in treatment naive HCV mono-infected per protocol (PP) population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.

  At 24 weeks after EOT

• Percentage of Participants With Modified Sustained Virological Response Over Time by Type of Peginterferon and Genotype in Modified All Treated Population

  Modified sustained virological response (mSVR) was defined as modified virological response (mVR) of HCV RNA \<50 IU/mL at 24 weeks after EOT. The mSVR is reported in treatment naive HCV mono-infected mTRT population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.

  At 24 weeks after EOT

• Percentage of Participants With Modified Sustained Virological Response by Type of Peginterferon and Genotype in Per Protocol Population

  Modified sustained virological response is defined as mVR of HCV RNA \<50 IU/mL at 24 weeks after EOT. The mSVR is reported in treatment naive HCV mono-infected PP population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.

  At 24 weeks after EOT

• Percentage of Participants With Predictive Values of Virological Response by Week 4 and 12 on Modified Sustained Virological Response After Treatment Initiation in Modified All Treated Population

  The probability that a participant who developed VR by Week 4 and 12 and also achieved mSVR at 24 weeks after EOT was called the positive predictive value (PPV) of the VR by Wk 4 for mSVR. The probability that a participant who failed to develop VR by Wk 4 and 12 and also failed to achieve mSVR at 24 weeks after EOT was called the negative predictive value (NPV) of the VR by Wk 4 and 12 for mSVR. Predictive values of VR are reported in treatment naive HCV mono-infected mTRT participants who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.

  At 24 weeks after EOT

• Percentage of Participants With Predictive Values of Virological Response by Week 4 and 12 on Modified Sustained Virological Response After Treatment Initiation in Per Protocol Population

  The probability that a participant who developed VR by Week 4 and 12 and also achieved mSVR at 24 weeks after EOT was called the PPV of the VR by Wk 4 for mSVR. The probability that a participant who failed to develop VR by Wk 4 and 12 and also failed to achieve mSVR at 24 weeks after EOT was called the NPV of the VR by Wk 4 and 12 for mSVR. Predictive values of VR are reported in treatment naive HCV mono-infected PP population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.

  At 24 weeks after EOT

Secondary Outcomes (16)

• Percentage of Participants With Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population Over Time

  At Week 2, Week 4, Week 12, EOT, and at 12 Weeks after EOT

• Percentage of Participants With Virological Response by Type of Peginterferon and Genotype in Per Protocol Population Over Time

  At Week 2, Week 4, Week 12, EOT, and at 12 Weeks after EOT

• Percentage of Participants With Modified Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population Over Time

  At Week 2, Week 4, Week 12, EOT, and at 12 Weeks after EOT

• Percentage of Participants With Modified Virological Response by Type of Peginterferon and Genotype in Per Protocol Population Over Time

  At Week 2, Week 4, Week 12, EOT, and at 12 Weeks after EOT

• Percentage of Participants With at Least a 2-log10 Drop in Hepatitis C Virus Ribonucleic Acid in Modified All Treated Population at Week 2, Week 4 and Week 12

  At Week 2, Week 4 and Week 12

Study Arms (1)

Cohort

Participants chronically infected with the hepatitis C virus including genotypes 1 to 6.

Drug: Peginterferon alfa-2a [Pegasys]; Drug: Peginterferon alfa-2b [PegIntron®]

Interventions

Peginterferon alfa-2a [Pegasys] DRUG

Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.

Cohort

Peginterferon alfa-2b [PegIntron®] DRUG

Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.

Cohort

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients receiving peginterferon alfa treatment at a medical centre

You may qualify if:

• adult patients, \>/= 18 years of age
• chronic hepatitis C
• HIV HCV co-infection allowed
• informed consent to data collection

You may not qualify if:

• co-infection with Hepatitis B Virus (HBV)
• previous treatment with peginterferon and/or ribavirin

Sponsors & Collaborators

• Hoffmann-La Roche: lead

Study Sites (106)

Unknown Facility

Birmingham, Alabama, 35233, United States

Location

Unknown Facility

Birmingham, Alabama, 35249, United States

Location

Unknown Facility

Birmingham, Alabama, 35294, United States

Location

Unknown Facility

Dothan, Alabama, 36305, United States

Location

Unknown Facility

Fresno, California, 93721, United States

Location

Unknown Facility

La Jolla, California, 92037-1030, United States

Location

Unknown Facility

Lancaster, California, 93534, United States

Location

Unknown Facility

Loma Linda, California, 92354, United States

Location

Unknown Facility

Long Beach, California, 90822, United States

Location

Unknown Facility

Los Angeles, California, 90048, United States

Location

Unknown Facility

Los Angeles, California, 90057, United States

Location

Unknown Facility

Los Angeles, California, 90095, United States

Location

Unknown Facility

Sacramento, California, 95817, United States

Location

Unknown Facility

San Clemente, California, 92679, United States

Location

Unknown Facility

San Diego, California, 92103-8465, United States

Location

Unknown Facility

San Francisco, California, 94115, United States

Location

Unknown Facility

San Mateo, California, 94403, United States

Location

Unknown Facility

Torrance, California, 90505, United States

Location

Unknown Facility

Aurora, Colorado, 80045, United States

Location

Unknown Facility

Hartford, Connecticut, 06106, United States

Location

Unknown Facility

Gainesville, Florida, 32610-0214, United States

Location

Unknown Facility

Maitland, Florida, 32751, United States

Location

Unknown Facility

Orlando, Florida, 32803, United States

Location

Unknown Facility

Orlando, Florida, 32806, United States

Location

Unknown Facility

Atlanta, Georgia, 30308, United States

Location

Unknown Facility

Decatur, Georgia, 30033, United States

Location

Unknown Facility

Macon, Georgia, 31201, United States

Location

Unknown Facility

Marietta, Georgia, 30060, United States

Location

Unknown Facility

Honolulu, Hawaii, 96813, United States

Location

Unknown Facility

Chicago, Illinois, 60612, United States

Location

Unknown Facility

Chicago, Illinois, 60637, United States

Location

Unknown Facility

Iowa City, Iowa, 52242, United States

Location

Unknown Facility

Kansas City, Kansas, 66160, United States

Location

Unknown Facility

Lexington, Kentucky, 40536-0298, United States

Location

Unknown Facility

Baton Rouge, Louisiana, 70890, United States

Location

Unknown Facility

New Orleans, Louisiana, 70121, United States

Location

Unknown Facility

Opelousas, Louisiana, 70520, United States

Location

Unknown Facility

Annapolis, Maryland, 21401, United States

Location

Unknown Facility

Baltimore, Maryland, 21229, United States

Location

Unknown Facility

Boston, Massachusetts, 02114, United States

Location

Unknown Facility

Springfield, Massachusetts, 01103, United States

Location

Unknown Facility

Springfield, Massachusetts, 01107-1635, United States

Location

Unknown Facility

Worcester, Massachusetts, 01068, United States

Location

Unknown Facility

Detroit, Michigan, 48201, United States

Location

Unknown Facility

Grand Rapids, Michigan, 49506, United States

Location

Unknown Facility

Jackson, Mississippi, 39202, United States

Location

Unknown Facility

Tupelo, Mississippi, 38801, United States

Location

Unknown Facility

St Louis, Missouri, 63104, United States

Location

Unknown Facility

St Louis, Missouri, 63110, United States

Location

Unknown Facility

Topeka, Missouri, 66606, United States

Location

Unknown Facility

Lebanon, New Hampshire, 03756, United States

Location

Unknown Facility

Egg Harbour Township, New Jersey, 08234, United States

Location

Unknown Facility

Hackensack, New Jersey, 07601, United States

Location

Unknown Facility

Hillsborough, New Jersey, 08844, United States

Location

Unknown Facility

Roseland, New Jersey, 07068, United States

Location

Unknown Facility

Voorhees Township, New Jersey, 08043, United States

Location

Unknown Facility

Albuquerque, New Mexico, 87131, United States

Location

Unknown Facility

Bayside, New York, 11358, United States

Location

Unknown Facility

Catskill, New York, 12414, United States

Location

Unknown Facility

Flushing, New York, 11355, United States

Location

Unknown Facility

New York, New York, 10003, United States

Location

Unknown Facility

New York, New York, 10016, United States

Location

Unknown Facility

Poughkeepsie, New York, 12601, United States

Location

Unknown Facility

Syracuse, New York, 13210, United States

Location

Unknown Facility

Asheville, North Carolina, 28801, United States

Location

Unknown Facility

Chapel Hill, North Carolina, 27599-7584, United States

Location

Unknown Facility

Charlotte, North Carolina, 28211, United States

Location

Unknown Facility

Fayetteville, North Carolina, 28304, United States

Location

Unknown Facility

Rocky Mount, North Carolina, 27804, United States

Location

Unknown Facility

Winston-Salem, North Carolina, 27103, United States

Location

Unknown Facility

Winston-Salem, North Carolina, 27157, United States

Location

Unknown Facility

Cincinnati, Ohio, 45219, United States

Location

Unknown Facility

Cleveland, Ohio, 44106, United States

Location

Unknown Facility

Cleveland, Ohio, 44109, United States

Location

Unknown Facility

Cleveland, Ohio, 44195, United States

Location

Unknown Facility

Oklahoma City, Oklahoma, 73112-4481, United States

Location

Unknown Facility

Tulsa, Oklahoma, 74135, United States

Location

Unknown Facility

Medford, Oregon, 97504, United States

Location

Unknown Facility

Portland, Oregon, 97227, United States

Location

Unknown Facility

Portland, Oregon, 97239, United States

Location

Unknown Facility

Camp Hill, Pennsylvania, 17011, United States

Location

Unknown Facility

DuBois, Pennsylvania, 15801, United States

Location

Unknown Facility

Pittsburgh, Pennsylvania, 15213, United States

Location

Unknown Facility

Bristol, Tennessee, 37620, United States

Location

Unknown Facility

Chattanooga, Tennessee, 37403, United States

Location

Unknown Facility

Germantown, Tennessee, 38138, United States

Location

Unknown Facility

Kingsport, Tennessee, 37660, United States

Location

Unknown Facility

Nashville, Tennessee, 37211, United States

Location

Unknown Facility

West Nashville, Tennessee, 37205, United States

Location

Unknown Facility

Dallas, Texas, 75203, United States

Location

Unknown Facility

Galveston, Texas, 77555, United States

Location

Unknown Facility

Harlingen, Texas, 78550, United States

Location

Unknown Facility

Houston, Texas, 77030, United States

Location

Unknown Facility

Houston, Texas, 77074, United States

Location

Unknown Facility

Houston, Texas, 77090, United States

Location

Unknown Facility

San Antonio, Texas, 78229, United States

Location

Unknown Facility

San Antonio, Texas, 78234, United States

Location

Unknown Facility

Salt Lake City, Utah, 84121, United States

Location

Unknown Facility

Charlottesville, Virginia, 22908, United States

Location

Unknown Facility

Fairfax, Virginia, 22031, United States

Location

Unknown Facility

Norfolk, Virginia, 23502, United States

Location

Unknown Facility

Richmond, Virginia, 23298, United States

Location

Unknown Facility

Seattle, Washington, 98133, United States

Location

Unknown Facility

Huntington, West Virginia, 25701, United States

Location

Unknown Facility

Casper, Wyoming, 82609, United States

Location

Unknown Facility

Santurce, 00909, Puerto Rico

Location

Related Publications (1)

• Ferenci P, Aires R, Ancuta I, Arohnson A, Cheinquer H, Delic D, Gschwantler M, Larrey D, Tallarico L, Schmitz M, Tatsch F, Ouzan D. A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin. Liver Int. 2014 Nov;34(10):1550-9. doi: 10.1111/liv.12439. Epub 2014 Jan 9.

  PMID: 24329937 DERIVED

MeSH Terms

Conditions

Hepatitis C, Chronic

Interventions

peginterferon alfa-2a; peginterferon alfa-2b

Condition Hierarchy (Ancestors)

Hepatitis C; Blood-Borne Infections; Communicable Diseases; Infections; Hepatitis, Viral, Human; Virus Diseases; Flaviviridae Infections; RNA Virus Infections; Hepatitis, Chronic; Hepatitis; Liver Diseases; Digestive System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: Roche Trial Information Hotline
• Organization: F. Hoffmann-La Roche AG

global.trial_information@roche.com

+41 61 6878333

Study Officials

• Clinical Trials

  Hoffmann-La Roche

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 9, 2010
• First Posted: February 10, 2010
• Study Start: January 1, 2008
• Primary Completion: August 1, 2011
• Study Completion: August 1, 2011
• Last Updated: August 8, 2016
• Results First Posted: August 8, 2016

Record last verified: 2016-06

Locations

US (105); PR (1)